Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: Development and biopharmacological profiling of 7-[(3-chlorobenzyl) oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6685-6706

  Pisani, Leonardo ^a   Muncipinto, Giovanni ^a   Miscioscia, Teresa Fabiola ^a   Nicolotti, Orazio ^a   Leonetti, Francesco ^a   Catto, Marco ^a   Caccia, Carla ^b   Salvati, Patricia ^b   Soto Otero, Ramon ^c   Mendez Alvarez, Estefania ^c   Passeleu, Celine ^d   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Newron Pharmaceuticals Spa   (Italy)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(BENZYLAMINO)METHYL] 7 [(3 CHLOROBENZYL)OXY] 2H CHROMEN 2 ONE; 4 [(ETHYLAMINO)METHYL] 7 [(3 FLUOROBENZYL)OXY] 2H CHROMEN 2 ONE METHANESULFONATE; 4 [[BENZYL(METHYL)AMINO]METHYL] 7 [(3-CHLOROBENZYL)OXY] 2H CHROMEN 2 ONE; 4 AMINOETHYLCOUMARIN DERIVATIVE; 4 CYANOMETHYLCOUMARIN DERIVATIVE; 7 [(3 CHLOROBENZYL)OXY] 4 [(METHYLAMINO)METHYL] 2H CHROMEN 2 ONE METHANESULFONATE; 7 [(3 FLUOROBENZYL)OXY] 4 [(ISOPROPYLAMINO)METHYL] 2H CHROMEN 2 ONE METHANESULFONATE; 7 [(3 FLUOROBENZYL)OXY] 4 [(METHYLAMINO)METHYL] 2H CHROMEN 2 ONE METHANESULFONATE; 7 PYRIDYLMETHOXYCOUMARIN DERIVATIVE; AMIDOAMINOCOUMARIN DERIVATIVE; BENZOIC ACID; COUMARIN DERIVATIVE; CYTOCHROME P450; MONOAMINE OXIDASE B INHIBITOR; NW 1772; UMBELLIFERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME BINDING; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT; SIMULATION; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; HUMANS; ISOENZYMES; MEMBRANES, ARTIFICIAL; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PERMEABILITY; PROTEIN BINDING; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049173711     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9010127     Document Type: Article

References (87)

1. Strolin-Benedetti, M.; Tipton, K. F.; Whomsley, R. Amine Oxidases and Monooxygenases in the in Vivo Metabolism of Xenobiotic Amines in Humans: Has the Involvement of Amine Oxidases Been Neglected? Fundam. Clin. Pharmacol. 2007, 21, 467-479.
2. Shih, J. C.; Chen, K.; Ridd, M. J. Monoamine Oxidase: From Genes to Behaviour. Annu. Rev. Neurosci. 1999, 22, 197-217.
3. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and Mechanism of Monoamine Oxidases. Curr. Med. Chem. 2004, 11, 1983-1993.
4. Edmondson, D. E.; Binda, C.; Wang, J.; Upadhyay, A. K.; Mattevi, A. Molecular and Mechanistic Properties of the Membrane-Bound Mitochondrial Monoamine Oxidases. Biochemistry 2009, 26, 4220-4230.
5. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Structure of Human Monoamine Oxidase B, a Drug Target for a Treatment of Neurological Disorders. Nat. Struct. Biol. 2002, 9, 22-26.
6. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Insights into the Mode of Inhibition of Human Mitochondrial Monoamine Oxidase B from High-Resolution Crystal Structures. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9750-9755.
7. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Three-Dimensional Structure of Human Monoamine Oxidase A (MAO A): Relation to the Structures of Rat MAO A and Human MAO B. Proc. Natl. Acad. Sci.U.S.A. 2005, 102, 12684-12689.
8. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of Rat Monoamine Oxidase A and Its Specific Recognitions for Substrates and Inhibitors. J. Mol. Biol. 2004, 338, 103-114.
9. Grimsby, J.; lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue Distribution of Human Monoamine Oxidase-A and Oxidase-B Messenger-RNA. J. Neurochem. 1990, 55, 1166-1169.
10. Fowler, C. J.; Ross, S. B. Selective Inhibitors of Monoamine Oxidase A and B: Biochemical, Pharmacological, and Clinical Properties. Med. Res. Rev. 1984, 4, 323-358.
11. Youdim, M. B.; Bakhle, Y. S. Monoamine Oxidase: Isoforms and Inhibitors in Parkinson's Disease and Depressive Illness. Br. J. Pharmacol. 2006, 147, S287-S296.
12. Yamada, M.; Yasuhara, H. Clinical Pharmacology of MAO Inhibitors: Safety and Future. Neurotoxicology 2004, 25, 215-221. (Pubitemid 38044183)
13. Lewitt, P. A. MAO-B Inhibitor Know-How: Back to the Pharm. Neurology 2009, 72, 1352-1357.
14. Youdim, M. B.; Edmondson, D. E.; Tipton, K. F. The Therapeutic Potential of Monoamine Oxidase Inhibitors. Nat. Rev. Neurosci. 2006, 7, 295-309.
15. Haefely, W. E.; Burkard, W. P.; Cesura, A. M.; Kettler, R.; Lorez, H. P.; Martin, J. R.; Richards, J. G.; Scherschlicht, R.; DaPrada, M. Biochemistry and Pharmacology of Moclobemide, a Prototype RIMA. Psychopharmacology 1992, 106, 6-14.
16. Fernandez, H. H.; Chen, J. J. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease. Pharmacotherapy 2007, 27, S174-S185.
17. Onofrj, M.; Bonanni, L.; Thomas, A. An Expert Opinion on Safinamide in Parkinson's Disease. Expert. Opin. Invest. Drugs 2008, 17, 1115-1125.
18. Chen, J. J.; Swope, D. M.; Dashtipour, K. Comprehensive Review of Rasagiline, a Second-Generation Monoamine Oxidase Inhibitor, for the Treatment of Parkinson's Disease. Clin. Ther. 2007, 29, 1825-1849.
19. Olanow, C. W.; Hauser, R. A.; Jankovic, J.; Langston, W.; Lang, A.; Poewe, W.; Tolosa, E.; Stocchi, F.; Melamed, E.; Eyal, E.; Rascol, O. A. Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study To Assess Rasagiline as a Disease Modifying Therapy in Parkinson's Disease (the ADAGIO Study): Rationale, Design, and Baseline Characteristics. Movement Disord. 2008, 23, 2194-2201.
20. Lee, K. C.; Chen, J. J. Transdermal Selegiline for the Treatment of Major Depressive Disorder. Neuropsychiatr. Dis. Treat. 2007, 3, 527-537.
21. Thorpe, L. W.; Westlund, K. N.; Kochensperger, L. M.; Abell, C. W.; Denney, R. M. Immunocytochemical Localization of Monoamine Oxidases A and B in Human Peripheral Tissues and Brain. J. Histochem. Cytochem. 1987, 35, 23-32.
22. Strolin Benedetti, M.; Dostert, P. Monoamine Oxidase, Brain Aging and Degenerative Diseases. Biochem. Pharmacol. 1989, 38, 555-561.
23. Saura, J.; Andres, N.; Andrade, C.; Ojuel, J.; Eriksson, K.; Mahy, N. Biphasic and Region-Specific MAO-B Response to Aging in Normal Human Brain. Neurobiol. Aging 1997, 18, 497-507.
24. Fowler, C. J.; Wiberg, A.; Oreland, L.; Marcusson, J.; Winblad, B. The Effect of Age on the Activity and Molecular Properties of Human Brain Monoamine Oxidase. J. Neural Transm. 1980, 49, 1-20. (Pubitemid 10030548)
25. Kovacic, P. Oxidative Stress. Curr. Med. Chem. 2001, 8, 721-863.
26. Barnham, K. J.; Masters, C. L.; Bush, A. I. Neurodegenerative Diseases and Oxidative Stress. Nat. Rev. 2004, 3, 205-214.
27. Halliwell, B. Oxidative Stress and Neurodegeneration: Where Are We Now? J. Neurochem. 2006, 97, 1634-1658.
28. Hermida-Ameijeiras, A.; Mendez-Alvarez, E.; Sanchez-Iglesias, S.; Sanmartin-Suarez, C.; Soto-Otero, R. Autoxidation and MAO-Mediated Metabolism of Dopamine as a Potential Cause of Oxidative Stress: Role of Ferrous and Ferric Ions. Neurochem. Int. 2004, 45, 103-116.
29. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine Oxidase-B Inhibition in Alzheimer's Disease. Neurotoxicology 2004, 25, 271-277. (Pubitemid 38044188)
30. Thomas, T. Monoamine Oxidase-B Inhibitors in the Treatment of Alzheimers Disease. Neurobiol. Aging 2000, 21, 343-348. (Pubitemid 30387093)
31. Ebadi, M.; Sharma, S.; Shavali, S.; El Refaey, H. Neuroprotective Actions of Selegiline. J. Neurosci. Res. 2002, 67, 285-289.
32. Eliash, S.; Dror, V.; Cohen, S.; Rehavi, M. Neuroprotection by Rasagiline in Thiamine Deficient Rats. Brain Res. 2009, 1256, 138-148.
33. Sano, M.; Ernesto, C.; Thomas, R. G.; Klauber, M. R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C. W.; Pfeiffer, E.; Schneider, L. S.; Thal, L. J. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease. N. Engl. J. Med. 1997, 336, 1216-1222.
34. Schneider, L. S.; Olin, J. T.; Pawluczyk, S. A Double-Blind Crossover Pilot Study of l-Deprenyl (Selegiline) Combined with Cholinesterase Inhibitor in Alzheimer's Disease. Am. J. Psychiatry 1993, 150, 321-323. (Pubitemid 23046522)
35. Tolbert, S. R.; Fuller, M. A. Selegiline in Treatment of Behavorial and Cognitive Symptoms in Alzheimer's Disease. Ann. Pharmacother. 1996, 30, 1122-1129.
36. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D. E.; Mattevi, A. Crystal Structures of MAO B in Complex with Four Inhibitors of the N-Propargylaminoindan Class. J. Med. Chem. 2004, 47, 1767-1774.
37. Son, S. Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of Human Monoamine Oxidase A at 2.2-Å Resolution: The Control of Opening the Entry for Substrates/Inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5739-5744.
38. Novaroli, L.; Reist, M.; Favre, E.; Carotti, A.; Catto, M.; Carrupt, P. A. Human Recombinant Monoamine Oxidase B as Reliable and Efficient Enzyme Source for Inhibitor Screening. Bioorg. Med. Chem. 2005, 13, 6212-6217.
39. Bravo, J. Development and Validation of Target-Based Drug Design Tools: Virtual Screening of Monoamine Oxidase Inhibitors. Ph.D. Thesis, Faculté des Sciences, Université de Genève, Switzerland, April 2009.
40. Kneubuhler, S.; Carta, V.; Altomare, C.; Carotti, A.; Testa, B. Synthesis and Monoamine Oxidase Inhibitory Activity of 3-Substituted 5H-Indeno[1,2-c] pyridazines. Helv. Chim. Acta 1993, 76, 1954-1963.
41. Kneubuhler, S.; Thull, U.; Altomare, C.; Carta, V.; Gaillard, P.; Carrupt, P.-A.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidase-B by 5H-Indeno[1,2-c]pyridazines. Biological Activities, Quantitative Structure-Activity-Relationships (QSARs) and 3D-QSARs. J. Med. Chem. 1995, 38, 3874-3883.
42. Altomare, C.; Cellamare, S.; Summo, L.; Catto, M.; Carotti, A.; Thull, U.; Carrupt, P. A.; Testa, B.; Stockli-Evans, H. Inhibition of Monoamine Oxidase-B by Condensed Pyridazines and Pyrimidines; Effects of Lipophilicity and Structure-Activity Relationships. J. Med. Chem. 1998, 41, 3812-3820.
43. Thull, U.; Kneubuhler, S.; Gaillard, P.; Carrupt, P.-A.; Testa, B.; Altomare, C.; Carotti, A.; Jenner, P.; McNaught, K. S. P. Inhibition of Monamine Oxidase by Isoquinoline Derivatives: Qualitative and 3D-Quantitative Structure-Activity Relationships. Biochem. Pharmacol. 1995, 50, 869-877.
44. Carotti, A.; Carrieri, A.; Chimichi, S.; Boccalini, M.; Cosimelli, B.; Gnerre, C.; Carotti, A.; Carrupt, P. A.; Testa, B. Natural and Synthetic Geiparvarins Are Strong and Selective MAO-B Inhibitors. Synthesis and SAR Studies. Bioorg. Med. Chem. Lett. 2002, 12, 3551-3555.
45. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidases by Functionalized Coumarin Derivatives: Biological Activities, QSARs, and 3D-QSARs. J. Med. Chem. 2000, 43, 4747-4758. (Pubitemid 32002686)
46. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A. D.; Soto-Otero, R.; Mendez-Alvarez, E.; Carotti, A. Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7-Substituted Coumarins from Ligand- and Target-Based Approaches. J. Med. Chem. 2006, 49, 4912-4925.
47. Bruhlmann, C.; Ooms, F.; Carrupt, P.-A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarin Derivatives as Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase. J. Med. Chem. 2001, 44, 3195-3198.
48. Carotti, A.; Melloni, P.; Thaler, F.; Caccia, C.; Maestroni, S.; Salvati, P. Substituted Aminoalkyl and Amidoalkyl Benzopyran Derivatives. WO 2006/102958 A1, 2006.
49. Rendenbach-Muller, B.; Schlecker, R.; Traut, M.; Weifenbach, H. Synthesis of Coumarins as Subtype-Selective Inhibitors of Monoamine Oxidase. Bioorg. Med. Chem. Lett. 1994, 4, 1195-1198.
50. Rendenbach, B.; Weifenbach, H.; Teschendorf, H. J. Arylalkoxycumarine. Verfahren zu Ihre Herstellung und Diese Enthalende Therapeutische Mittel. Patent DE 3834861 A1, 1990 (BASFAG).
51. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Inhibition of Monoamine Oxidases by Coumarin-3-acyl Derivatives: Biological Activity and Computational Study. Bioorg.Med.Chem. Lett. 2004, 14, 3697-3703.
52. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, Molecular Modeling, and Selective Inhibitory Activity against Human Monoamine Oxidases of 3-Carboxamido-7-substituted Coumarins. J. Med. Chem. 2009, 52, 1935-1942.
53. Santana, L.; Gonzalez-Diaz, H.; Quezada, E.; Uriarte, E.; Yanez, M.; Vina, D.; Orallo, F. Quantitative Structure-Activity Relationship and Complex Network Approach to Monoamine Oxidase A and B Inhibitors. J. Med. Chem. 2008, 51, 6740-6751.
54. Carotti, A. MAOs Long March: From Toxic First-Generation Drugs to Isoform-Selective, Reversible and Multi-Target Inhibitors. Presented at the Meeting of ACS-EFMC, Frontiers in CNS and Oncology Medicinal Chemistry, Siena, Italy, October 7-9, 2007.
55. v. Pechmann, H. Novel Synthesis of Coumarins. Ber. Dtsch. Chem. Ges. 1884, 17, 929-936.
56. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D. E.; Mattevi, A. Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs. J. Med. Chem. 2007, 50, 5848-5852.
57. Campos-Toimil, M.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and Vasorelaxant Activity of New Coumarin and Furocoumarin Derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 783-786.
58. Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1, 1-29.
59. Vaultier, M.; Knouzi, N.; Carrie, R. Reductiòn d'Azides en Amines Primaires par une Methode Generale Utilisant la Reaction de Staudinger. Tetrahedron Lett. 1983, 24, 763-764.
60. Bartra, M.; Romea, P.; Urpì, F.; Villarasa, J. A Fast Procedure for the Reduction of Azides and Nitro Compounds Based on the Reducing Ability of Sn(SR)3-Species. Tetrahedron 1990, 46, 587-594.
61. Campagna, F.; Carotti, A.; Casini, G. A Convenient Synthesis of Nitriles from Primary Amides under Mild Conditions. Tetrahedron Lett. 1977, 21, 1813-1816.
62. Martel S.; Gasparik, V.; Carrupt P. A. In Silico Tools and in Vitro HTS Approaches To Determine Lipophilicity during the Drug Discovery Process. In Hit and Lead Profiling; Faller, B., Urban, L., Eds.; Wiley-VCH: Weinheim, Germany, 2009.
63. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches To Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
64. Fernández, F.; Caamaño, O.; Nieto, M. I.; López, C.; García-Mera, X.; Stefanachi, A.; Nicolotti, O.; Loza, M. I.; Brea, J.; Esteve, C.; Segarra, V.; Vidal, B.; Carotti, A. 1,3-Dialkyl-8-N-substituted Benzyloxycarbonylamino-9-deazaxanthines as Potent Adenosine Receptor Ligands: Design, Synthesis, Structure-Affinity and Structure-Selectivity Relationships. Bioorg. Med. Chem. 2009, 17, 3618-3629.
65. Wohnsland, F.; Faller, B. High-throughput Permeability pH Profile and High-Throughput Alkane/Water logP with Artificial Membranes. J. Med. Chem. 2001, 44, 923-930.
66. Henchoz, Y.; Bard, B.; Guillarme, D.; Carrupt, P. A.; Veuthey, J. L.; Martel, S. Analytical Tools for Physicochemical Profiling of Drug Candidates To Predict Absorption/Distribution. Anal. Bioanal. Chem. 2009, 394, 707-729.
67. Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R. G. Safinamide: From Molecular Targets to a New Anti-Parkinson Drug. Neurology 2006, 67, S18-S23. (Pubitemid 44568830)
68. Robinson, D. S.; Lovenberg, W.; Keiser, H.; Sjoerdsma, A. Effects of Drugs on Human Blood Platelet and Plasma Amine Oxidase Activity in Vitro and in Vivo. Biochem. Pharmacol. 1968, 17, 109-119.
69. Malich, G.; Markovic, B.; Winder, C. The Sensitivity and Specificity of the MTS Tetrazolium Assay for Detecting the in Vitro Toxicity of 20 Chemicals Using Human Cell Lines. Toxicology 1997, 124, 179-192. (Pubitemid 28055528)
70. Guba, W.; Roche, O. Computational Filters in Lead Generation: Targeting Drug-like Molecules. In Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective; Kubinyi, H., Folkers, G., Eds.; Wiley-VCH: Weinheim, Germany, 2004; pp 325-340.
71. Pajouhesh, H.; Lenz, G. R. Medicinal Chemical Properties of Successful Central Nervous System Drugs. NeuroRx 2005, 2, 541-553. (Pubitemid 41393264)
72. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.; Jenner, P.; Testa, B. Lipophilicity Plays a Major Role in Modulating the Inhibition of Monoamine Oxidase B by 7-Substituted Coumarins. Chem. Biodiversity 2006, 3, 134-149. (Pubitemid 43322991)
73. Amadasi, A.; Surface, J. A.; Spyrakis, F.; Cozzini, P.; Mozzarelli, A.; Kellogg, G. E. Robust Classification of "Relevant" Water Molecules in Putative Protein Binding Sites. J. Med. Chem. 2008, 51, 1063-1067.
74. Barillari, C.; Taylor, J.; Viner, R.; Essex, J. W. Classification of Water Molecules in Protein Binding Sites. J. Am. Chem. Soc. 2007, 129, 2577-2587.
75. Lu, Y.; Wang, R.; Yang, C.Y.; Wang, S. Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes. J. Chem. Inf. Model. 2007, 47, 668-675.
76. Cavasotto, C. N.; Orry, A. J. W. Ligand Docking and Structure-Based Virtual Screening in Drug Discovery. Curr. Top. Med. Chem. 2007, 7, 1006-1014.
77. Roberts, B. C.; Mancera, R. L. Ligand-Protein Docking with Water Molecules. J. Chem. Inf. Model. 2008, 48, 397-408.
78. Huang, N.; Shoichet, B. K. Exploiting Ordered Waters in Molecular Docking. J. Med. Chem. 2008, 51, 4862-4865.
79. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
80. Avdeef, A. Absorption and Drug Development: Solubility, Permeability, and Charge State; John Wiley & Sons: Hoboken, NJ, 2003.
81. Cruciani, G.; Crivori, P.; Carrupt, P. A.; Testa, B. Molecular Fields in Quantitative Structure-Permeation Relationships: The VolSurf Approach. J. Mol. Struct.: THEOCHEM 2000, 503, 17-30.
82. Crivori, P.; Cruciani, G.; Carrupt, P. A.; Testa, B. Predicting Blood-Brain Barrier Permeation from Three-Dimensional Molecular Structure. J. Med. Chem. 2000, 43, 2204-2216.
83. Baker, M.; Rayens, W. Partial Least Squares for Discrimination. J. Chemom. 2003, 17, 166-173.
84. Munoz-Torrero, D. Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimer's Disease. Curr. Med. Chem. 2008, 15, 2433-2455.
85. Cavalli, A.; Bolognesi, M. L.; Melchiorre, C.; Minarini, A.; Rosini, M.; Recanatini, M. Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases. J. Med. Chem. 2008, 48, 347-372.
86. Kramer, S. D.; Gautier, J. C.; Saudemom, P. Considerations on the Potentiometric LogP Determination. Pharm. Res. 1998, 15, 1310-1313.
87. Avdeef, A.; Box, K. J.; Comer, J. E.; Gilges, M.; Hadley, M.; Hibbert, C.; Patterson, W.; Tam, K. Y. J. pH-metric log P 11. pKa determination of water-insoluble drugs in organic solvent-water mixtures. J. Pharm. Biomed. Anal. 1999, 20, 631-641.